Home » Stocks » PHAR

Pharming Group N.V. (PHAR)

Stock Price: $13.20 USD 0.60 (4.78%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 844.80M
Revenue (ttm) 226.46M
Net Income (ttm) 40.29M
Shares Out 64.00M
EPS (ttm) 0.59
PE Ratio 22.55
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $13.20
Previous Close $12.60
Change ($) 0.60
Change (%) 4.78%
Day's Open 12.84
Day's Range 12.98 - 13.50
Day's Volume 5,633
52-Week Range 12.24 - 21.99


Hide News

Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") under the s...

4 months ago - PR Newswire

Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical...

5 months ago - PR Newswire UK

Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About PHAR

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated ... [Read more...]

Research and Development in Biotechnology
Sijmen de Vries
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, Pharming Group's revenue was 185.69 million, an increase of 9.86% compared to the previous year's 169.02 million. Earnings were 33.04 million, a decrease of -8.73%.

Financial numbers in millions EUR.
Financial Statements